Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. The company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company's main capabilities include clinical development, vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. The company is conducting a clinical trial for its gene therapy candidate ADVM-022, AAV.7m8-aflibercept, for the treatment of wet age-related macular degeneration.

Anixa Biosciences is a biotechnology company focused on using the body's immune system to diagnose, treat and prevent cancer. The company's subsidiary, Anixa Diagnostics Corporation, develops Cchek?, a platform for non-invasive blood tests for the early detection of cancer. The company's subsidiary, Certainty Therapeutics, Inc., develops immuno-therapy drugs against cancer. The company has focused on the development of a treatment for ovarian cancer. The company is also engaged in limited patent licensing activities in the area of encrypted audio/video conference calling.

Barrett Business Services is a provider of business management solutions for small-and mid-sized companies. The company has two categories of services: Professional Employer Services, in which the company enters into a client services agreement to establish a co-employment relationship with each client company, assuming responsibility for payroll, payroll taxes, workers' compensation coverage and certain other administrative functions for the client's existing workforce; and Staffing, which includes on-demand or short-term staffing assignments, contract staffing, direct placement, and long-term or indefinite-term on-site management.

bluebird bio is a biotechnology company engaged in researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. The company has built a product platform with a range of therapeutic potential in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. The company is developing LentiGlobin gene therapy for sickle cell disease; Lenti-D gene therapy for cerebral adrenoleukodystrophy; and in collaboration with Bristol-Myers Squibb, the company is developing bb2121 (idecabtagene vicleucel) and bb21217 product candidates as treatments for multiple myeloma.

TrovaGene is a clinical-stage, oncology therapeutics company, taking a precision medicine approach to develop targeted therapies for the treatment of patients with leukemias, lymphomas and solid tumor cancers. The company's drug candidate, onvansertib, is an oral and highly-selective Polo-like Kinase 1 (PLK1) adenosine triphosphate competitive inhibitor. PLK1 is essential for regulating the cell division and maintaining genome stability in mitosis (cell division), spindle assembly, and DNA damage response. The company's intellectual property and proprietary technology enables it to analyze circulating tumor DNA and clinically actionable markers for predicting response to cancer therapies.

Century Bancorp is a bank holding company. Through its subsidiary, Century Bank and Trust Company, the company provides services to commercial enterprises, state and local governments and agencies, non-profit organizations and individuals. The company also provides securities brokerage services through a program called Investment Services at Century Bank, which is supported by LPL Financial, a third party securities brokerage business. The company grants single-family and multi-family residential loans, commercial and commercial real estate loans, municipal loans, and a variety of consumer loans. In addition, the company provides savings accounts, NOW accounts, demand deposits, time deposits and money market accounts.

Charles & Colvard manufactures, markets, and distributes Charles & Colvard Created Moissanite? (which the company refers to as moissanite or moissanite jewels) and finished jewelry featuring its proprietary moissanite gemstone for sale in the worldwide jewelry market. The company sells loose moissanite jewels and finished jewelry through various operating segments: its Online Channels segment, which comprises its charlesandcolvard.com website, e-commerce outlets, including marketplaces, drop-ship customers, and other e-commerce customers; and its Traditional segment, which consists of domestic and international distributors and retail customers.

Crinetics Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. CRN00808, the company's primary product candidate, establishes oral selective nonpeptide somatostatin receptor type 2 (sst2) biased agonists designed for the treatment of acromegaly. CRN01941, an oral nonpeptide sst2 biased agonist, is designed for the treatment of neuroendocrine tumors that originate from neuroendocrine cells commonly found in the gut, lung or pancreas. The company is developing a class of oral selective nonpeptide somatostatin type 5 receptor agonists designed to treat congenital hyperinsulinism.

Designer Brands is a footwear and accessories designer, producer and retailer. The company has three segments: U.S. Retail, which includes stores operated in the U.S. under the DSW Designer Shoe Warehouse banner and its related e-commerce site; Canada Retail, which includes stores operated in Canada under The Shoe Company, Shoe Warehouse, and DSW Designer Shoe Warehouse banners and related e-commerce sites; and Brand Portfolio, which includes sales from wholesale, serving retailers as the design and buying agent for products under private labels, and direct-to-consumer e-commerce sites. The company separates its merchandise into three categories: women's footwear; men's footwear; and accessories and other.

First Citizens BancShares is a holding company. Through its banking subsidiary, First-Citizens Bank & Trust Co. (FCB), the company provides a range of retail and commercial banking services. Loan services include various types of commercial, business and consumer lending. Deposit services include checking, savings, money market and time deposit accounts. The company's subsidiaries also provides mortgage lending, a trust department, wealth management services for businesses and individuals and other activities incidental to commercial banking. FCB's subsidiaries provide various investment products including annuities, discount brokerage services and third-party mutual funds.

Good Times Restaurants operates and franchises Bad Daddy's Burger Bar restaurants (Bad Daddy's) and Good Times Burgers & Frozen Custard (Good Times) restaurants. Bad Daddy's and Good Times are two distinctly different, yet complementary, restaurant concepts. Bad Daddy's operates in the casual dining segment of the restaurant industry. Bad Daddy's operates all of its company-owned restaurants under a table service / full-bar service model. The menu is comprised of burgers, salads, sandwiches, and appetizers. Good Times is a quick service restaurant concept offering hand crafted products. Good Times provides a menu of Angus beef and chicken.

Horizon Technology Finance is a finance company that lends to and invests in development-stage companies in the technology, life science, healthcare information and services and cleantech industries (collectively, Target Industries). The company focuses on making secured debt investments to venture capital backed companies in its Target Industries. The company is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company. The company also has elected to be treated as a regulated investment company. The company's investment activities, and its day-to-day operations, are managed by its advisor, Horizon Technology Finance Management LLC.

Landec designs, develops, manufactures and sells health and wellness products for food and biomaterials markets. The company operates its business in two reportable business segments: Curation Foods, and Lifecore. The Curation Foods business is comprised of Curation Foods' packaged vegetables business sold primarily under the Eat Smart? brand, O Olive Oil & Vinegar? olive oils and wine vinegars, and Yucatan? and Cabo Fresh? guacamole and avocado food products. Lifecore is involved in the manufactures of pharmaceutical-grade sodium hyaluronate in bulk form as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.

Leidos Holdings is a holding company. Through its subsidiaries, the company is engaged in a science, engineering and information technology that provides services and solutions in the defense, intelligence, civil and health markets. The company's defense solutions segment deploys solutions in the areas of intelligence surveillance and reconnaissance, enterprise information technology, integrated systems, cybersecurity and global services. The company's civil segment integrates and protects physical, digital and data domains. The company's health segment delivers solutions to federal and commercial customers that are responsible for the health and well-being of people including service members and veterans.

Marker Therapeutics is a clinical-stage immuno-oncology company focusing on the development and commercialization of cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is developing three primary technology platforms: a licensed peptide-based vaccine for the treatment of breast cancers that overexpresses Human Epidermal Growth Factor Receptor 2 (TPIV100/110); a licensed peptide-based vaccine for treating breast and ovarian cancers that overexpress Folate Receptor Alpha (TPIV200); and a wholly-owned nucleic acid-based vaccine technology (PolyStart?) for treatment of various cancers or infectious disease.

Marrone Bio Innovations makes bio-based pest management and plant health products. Bio-based products are comprised of naturally occurring microorganisms, such as bacteria and fungi, and plant extracts. The company primarily sells its products to the crop protection market and also have one plant health product, Haven, that reduces plant stress in drought and intense sunlight. The company's product lines are Regalia, for controlling plant disease and increasing plant health, Grandevo and Venerate, for insect and mite control, Majestene and its turf and ornamentals counterpart brand Zelto, for nematode control and Stargus and its row crop counterpart brand Amplitude, for downy mildew and white mold control.

Merchants Bancorp is a bank holding company. The company operates several lines of business, including multi-family housing and servicing, mortgage warehouse financing, retail and correspondent residential mortgage banking, agricultural lending and traditional community banking. The company's business segments are defined as multi-family mortgage banking, mortgage warehousing, and banking. The company's banking segment includes retail banking, commercial lending, agricultural lending, and retail and correspondent residential mortgage banking, and Small Business Administration lending.

Molecular Templates is a clinical-stage company focused on the discovery and development of biologic therapeutic for cancer and other serious diseases. The company utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies (ETBs). The company is developing ETBs for various targets, including CD20, CD38, HER2, PD-L1, CTLA-4, SLAMF-7, and CD45. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of various myeloma. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.

Mustang Bio is a clinical-stage biopharmaceutical company. In partnership with St. Jude Children's Research Hospital, the company's gene therapy program (MB-107) is being developed to treat X-linked severe combined immunodeficiency. The company is developing chimeric antigen receptor engineered T cell therapies for hematologic malignancies in partnership with the City of Hope National Medical Center targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutchinson Cancer Research Center targeting CD20 (MB-106). In addition, The company has partnered with Nationwide Children's Hospital for C134 (MB-108) in order to improve the activity of MB-101 for the treatment of patients with glioblastoma multiforme.

Myers Industries manufactures a range of polymer products for industrial, agricultural, automotive, commercial and consumer markets. The company has two business segments: Material Handling and Distribution. The Material Handling segment manufactures polymer packaging containers, storage and safety products, and specialty molded parts. The brands within this segment include Buckhorn?, Akro-Mils?, Jamco Products, Ameri-Kart?, and Scepter. The company's Distribution segment includes the Myers Tire Supply?, Myers Tire Supply International? and Patch Rubber Company? brands. Within the Distribution Segment Co. sources and manufactures products for the tire, wheel and undervehicle service industry.

OncoCyte is focused on developing non-invasive molecular diagnostic tests for cancer diagnosis. The company is developing DetermaVu?, a non-invasive molecular lung cancer confirmatory diagnostic that can be administered to patients as a blood test. DetermaVu? utilizes proprietary sets of gene expression markers to help confirm whether lung nodules detected via Low Dose Computed Tomography scans, x-rays or other imaging are likely to be benign or malignant. DetermaVu? is based on the company's Immune System Interrogation approach that checks the body's immune system response to a specific disease by measuring differential RNA expression in patients with the disease versus patients without the disease.

Overseas Shipholding Group is a holding company. Through its subsidiaries, the company owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products in the U.S. Flag trades. The company has one reportable business segment. The company's U.S. Flag Fleet consists of various owned and chartered-in Jones Act Handysize Product Carriers and Articulated Tug Barges and non-Jones Act U.S. Flag Handysize Product Carriers that participate in the U.S. Maritime Security Program. Under the Jones Act, shipping between U.S. ports, including the movement of Alaskan crude oil to U.S. ports, is reserved for U.S. Flag vessels.

Rocket Pharmaceuticals is a clinical-stage, multi-platform biotechnology company focused on the development of gene therapies for rare and devastating pediatric diseases. The company has the following inical-stage ex vivo lentiviral vector programs enrolling patients in the U.S. and European Union for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

Savara is an orphan lung disease company. The company's drug development pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor in development for pulmonary alveolar proteinosis and in development for nontuberculous mycobacterial lung infection; and AeroVanc, an inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis.

Solid Biosciences is engaged in the treatment of Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys, with symptoms that manifest between three and five years of age. The company's primary gene transfer candidate, SGT-001 is designed to address the underlying genetic cause of DMD by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. The company's portfolio also includes an initial disease modifying candidate, Anti-LTBP4, a monoclonal antibody designed to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein.

Support.com is engaged in outsourced call center and direct-to-consumer and small business technical support solutions. The company provides outsourced call center tech support services, cloud-based call center software, and tech support and anti-malware software. The company delivers support solutions, including presale and post-sale support across all devices in the connected home. Designed for both the consumer and small and medium-sized businesses end-user markets, the company's programs include a range of services for connected devices, including pre-purchase concierge advice, device set-up and troubleshooting, inter-operability problem resolution, and virus and malware removal.

Tiptree is a holding company. The company's principal operating subsidiary is a provider of specialty insurance products and related services. The company also allocates capital across a range of businesses, assets and other investments. The company's business is comprised of: specialty insurance, which underwrites and administers programs and products for its clients, including credit protection insurance, warranty and services contract products, and niche commercial and consumer insurance programs; and Tiptree Capital, which consists of its investment in Invesque Inc., asset management operations, mortgage operations, dry bulk shipping operations and other investments.

Trio-Tech International provides third-party semiconductor testing and burn-in services primarily through its laboratories in Asia. At or from its facilities, the company also designs, manufactures and markets equipment and systems to be used in the testing and production of semiconductors, and distributes semiconductor processing and testing equipment manufactured by other vendors. The company operates in four segments; the testing service industry (which performs structural and electronic tests of semiconductor devices), the designing and manufacturing of equipment distribution of various products from other manufacturers in Singapore and Asia and the real estate segment in China.

Tupperware Brands is a direct-to-consumer company engaged in the manufacture and sale of Tupperware? products and cosmetics and personal care products under a range of trade names, including Avroy Shlain?, Fuller?, NaturCare?, Nutrimetics? and Nuvo?. The company's products include: Tupperware, which includes preparation, storage, and serving solutions for the kitchen and home, and provides a line of cookware, knives, microwave products, microfiber textiles, water-filtration related items and a range of products for on-the-go consumers; and Beauty, which manufactures and distributes skin and hair care products, cosmetics, bath and body care, toiletries, fragrances, jewelry and nutritional products.

United Insurance Holdings is a holding company. Through its subsidiaries, the company is engaged in the residential personal and commercial property and casualty insurance business in the United States. The company's insurance subsidiaries provide personal residential and commercial property and casualty insurance products that protect its policyholders against losses due to damages to structures and their contents. Some of the company's insurance subsidiaries sell policies that protect against liability for accidents as well as property damage. The company's non-insurance subsidiaries support its insurance and investment operations. The company writes in Florida, Connecticut, Georgia, Hawaii, Louisiana, and other various states.

Vistra Energy operates an integrated retail and generation business in markets throughout the U.S. Through its subsidiaries, the company is engaged in electricity market activities, including electricity generation, wholesale energy sales and purchases, commodity risk management and retail sales of electricity. The company has six segments: Retail, ERCOT, PJM, NY/NE (comprising NYISO and ISO-NE), MISO and Asset Closure. The Retail segment is engaged in retail sales of electricity and related services. The ERCOT, PJM, NY/NE and MISO segments are engaged in electricity generation, among others. The Asset Closure segment is engaged in the decommissioning and reclamation of retired plants and mines.